Cargando…
The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up
It is difficult to treat cardiorenal syndrome (CRS) in clinical practice, which is the common reason for the death of patients. This report aimed to describe the effects of sacubitril/valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 (CRS4) after more t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962615/ https://www.ncbi.nlm.nih.gov/pubmed/35360715 http://dx.doi.org/10.3389/fmed.2022.817833 |
_version_ | 1784677839120891904 |
---|---|
author | Cheng, Shuiqin Zhou, Tingting Yu, Le Chen, Yunmin Zhang, Zhihong Wang, Jinquan Yu, Yusheng |
author_facet | Cheng, Shuiqin Zhou, Tingting Yu, Le Chen, Yunmin Zhang, Zhihong Wang, Jinquan Yu, Yusheng |
author_sort | Cheng, Shuiqin |
collection | PubMed |
description | It is difficult to treat cardiorenal syndrome (CRS) in clinical practice, which is the common reason for the death of patients. This report aimed to describe the effects of sacubitril/valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 (CRS4) after more than 3 years of follow-up. A 77-year-old Chinese woman was admitted to our hospital because of CRS4 and stage 5 chronic kidney disease (CKD), who had a history of long-term proteinuria and renal failure. The patient's cardiothoracic ratio (CTR) measured by chest X–ray was 0.6. Cardiac ultrasonography showed that the left ventricular ejection fraction (LVEF) was 0.40. The patient had been treated for heart failure (HF) for 5 months, but there was no improvement in clinical manifestations, and the renal function gradually deteriorated. In our hospital, she received sacubitril/valsartan treatment for at least 40 months. The symptoms of HF relieved, and the indices of cardiac function improved. In addition, the patient's renal function was stable. During the treatment, the dosage of sacubitril/valsartan needed to be adjusted to achieve the optimal therapeutic effect. Follow-up results showed that she achieved cardiac function of New York Heart Association (NYHA) class II with an ejection fraction of 0.60 and E/A > 1 indicated by echocardiogram, and did not develop hyperkalemia. In summary, the improvement of cardiac and renal functions of the CRS4 patient was associated with the long-term sacubitril/valsartan treatment. |
format | Online Article Text |
id | pubmed-8962615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89626152022-03-30 The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up Cheng, Shuiqin Zhou, Tingting Yu, Le Chen, Yunmin Zhang, Zhihong Wang, Jinquan Yu, Yusheng Front Med (Lausanne) Medicine It is difficult to treat cardiorenal syndrome (CRS) in clinical practice, which is the common reason for the death of patients. This report aimed to describe the effects of sacubitril/valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 (CRS4) after more than 3 years of follow-up. A 77-year-old Chinese woman was admitted to our hospital because of CRS4 and stage 5 chronic kidney disease (CKD), who had a history of long-term proteinuria and renal failure. The patient's cardiothoracic ratio (CTR) measured by chest X–ray was 0.6. Cardiac ultrasonography showed that the left ventricular ejection fraction (LVEF) was 0.40. The patient had been treated for heart failure (HF) for 5 months, but there was no improvement in clinical manifestations, and the renal function gradually deteriorated. In our hospital, she received sacubitril/valsartan treatment for at least 40 months. The symptoms of HF relieved, and the indices of cardiac function improved. In addition, the patient's renal function was stable. During the treatment, the dosage of sacubitril/valsartan needed to be adjusted to achieve the optimal therapeutic effect. Follow-up results showed that she achieved cardiac function of New York Heart Association (NYHA) class II with an ejection fraction of 0.60 and E/A > 1 indicated by echocardiogram, and did not develop hyperkalemia. In summary, the improvement of cardiac and renal functions of the CRS4 patient was associated with the long-term sacubitril/valsartan treatment. Frontiers Media S.A. 2022-03-11 /pmc/articles/PMC8962615/ /pubmed/35360715 http://dx.doi.org/10.3389/fmed.2022.817833 Text en Copyright © 2022 Cheng, Zhou, Yu, Chen, Zhang, Wang and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Cheng, Shuiqin Zhou, Tingting Yu, Le Chen, Yunmin Zhang, Zhihong Wang, Jinquan Yu, Yusheng The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up |
title | The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up |
title_full | The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up |
title_fullStr | The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up |
title_full_unstemmed | The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up |
title_short | The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up |
title_sort | effect of sacubitril/valsartan treatment on cardiac and renal functions of a patient with cardiorenal syndrome type 4 and stage 5 ckd after more than three years of follow-up |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962615/ https://www.ncbi.nlm.nih.gov/pubmed/35360715 http://dx.doi.org/10.3389/fmed.2022.817833 |
work_keys_str_mv | AT chengshuiqin theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT zhoutingting theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT yule theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT chenyunmin theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT zhangzhihong theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT wangjinquan theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT yuyusheng theeffectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT chengshuiqin effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT zhoutingting effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT yule effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT chenyunmin effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT zhangzhihong effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT wangjinquan effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup AT yuyusheng effectofsacubitrilvalsartantreatmentoncardiacandrenalfunctionsofapatientwithcardiorenalsyndrometype4andstage5ckdaftermorethanthreeyearsoffollowup |